Bioindicators Associated With Sarcopenia Before and After Intensive Lifestyle Intervention - Trial NCT06128577
Access comprehensive clinical trial information for NCT06128577 through Pure Global AI's free database. This Phase 4 trial is sponsored by Lijun Yang and is currently Completed. The study focuses on Sarcopenia. Target enrollment is 99 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Lijun Yang
Suzhou Municipal Hospital
Timeline & Enrollment
Phase 4
Mar 01, 2022
Aug 02, 2022
Primary Outcome
AMMI(appendicular muscle mass index)
Summary
The goal of this clinical trial is to explore whether the bioindicators of body composition,
 nutrition-related indicators (lymphocytes, albumin), lipids, and thyroid hormones are
 associated with sarcopenia and the changes in these indicators after an intensive lifestyle
 intervention. The main questions it aims to answer are:
 
 - whether the bioindicators such as lymphocytes, albumin, lipids, thyroid hormones, fat
 mass, fat-free mass, and basal metabolic mass are associated with the development of
 sarcopenia.
 
 - the changes of these bioindicators that occur in older adults after going through an
 intensive intervention.
 
 Participants will receive a 3-month intensive intervention consisting of an intensive
 nutritional intervention and an individually designed exercise intervention. Nutritional and
 exercise prescriptions are co-designed through a nutritionist and rehabilitation physician.
 
 Researchers will compare bioindicators in the sarcopenia group before and after intensive
 lifestyle intervention to determine the association with sarcopenia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06128577
Non-Device Trial